Frontlight ResearchEarly access
Taking people in United StatesPhase 2
Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 2
Key facts
- Who runs it
- Yale University
- Where
- West Haven, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 36 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Bupivacaine bilateral greater occipital nerve block
- Record updated
- 8 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- United States Military Veterans within VA Connecticut Healthcare System1
- Head injury with headaches that have continued to occur for at least three months after the head injury
- At least two headache days per week
- Review of the medical record does not reveal another source for headache
Who cannot take part
- Allergy or adverse reaction (e.g., rash, cardiac effects) to amide anesthetics, such as lidocaine
- Skull defect
- Other contraindication to bupivacaine
- Instruction from clinician to avoid amide anesthetics, such as lidocaine
- Pregnant or lack of adequate birth control
- Clinical review of the patient's case reveals red flag signs or symptoms (e.g., side-locked pain, unilateral numbness/weakness during headache, rapid ascension to peak pain, syncope during attacks) that warrant further work-up (e.g., MRI, arterial imaging)
- Absence of imaging warranted by the standard of clinical care for the head injury with headaches
This trial is currently available in United States.
- VA Connecticut Healthcare SystemWest Haven, United StatesContact: Emmanuelle Schindler, MD, PhDTaking people
About the trial
What the trial wants to find out
Anesthetic greater occipital nerve (GON) blockade is a simple, inexpensive, and safe procedure that has demonstrable headache pain suppressing effects. In this study, Veterans with post-traumatic headache will be randomized to receive 0.0%, 0.05%, or 0.5% bupivacaine in bilateral GON blocks and the lasting (i.e., transitional) effects on headache frequency measured in a headache diary.
The 3 groups in the trial
- PlaceboPlacebo, for comparison
0.0% bupivacaine (normal saline)
Treatment: Bupivacaine bilateral greater occipital nerve block
- Low dose bupivacaineExisting treatment, for comparison
0.05% bupivacaine
Treatment: Bupivacaine bilateral greater occipital nerve block
- Full dose bupivacaineTreatment being tested
0.5% bupivacaine
Treatment: Bupivacaine bilateral greater occipital nerve block
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Anesthetic Greater Occipital Nerve Blockade in Veterans With Post-Traumatic Headache: Sub-study 2
- Record updated
- 8 September 2026